Holy Stone Healthcare Co., Ltd.
Holy Stone Healthcare Co., Ltd. develops and sells hyaluronic acid-related therapeutic products in Taiwan. The company offers RenehaVis, a product designed to relive pain and stiffness of the knee joint; SportVis, a treatment to relive the pain and optimize the recovery of tendon and ligament injuries; TRUD, a treatment that allows mucosal tissue to heal naturally and reduces the symptoms of ulce… Read more
Holy Stone Healthcare Co., Ltd. (4194) - Net Assets
Latest net assets as of December 2025: NT$182.84 Million TWD
Based on the latest financial reports, Holy Stone Healthcare Co., Ltd. (4194) has net assets worth NT$182.84 Million TWD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$220.52 Million) and total liabilities (NT$37.68 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$182.84 Million |
| % of Total Assets | 82.91% |
| Annual Growth Rate | -19.17% |
| 5-Year Change | -30.76% |
| 10-Year Change | N/A |
| Growth Volatility | 115.9 |
Holy Stone Healthcare Co., Ltd. - Net Assets Trend (2019–2025)
This chart illustrates how Holy Stone Healthcare Co., Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Holy Stone Healthcare Co., Ltd. (2019–2025)
The table below shows the annual net assets of Holy Stone Healthcare Co., Ltd. from 2019 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$182.84 Million | -37.82% |
| 2024-12-31 | NT$294.07 Million | +252.74% |
| 2023-12-31 | NT$83.37 Million | -84.05% |
| 2022-12-31 | NT$522.74 Million | +97.95% |
| 2021-12-31 | NT$264.07 Million | -41.48% |
| 2020-12-31 | NT$451.27 Million | -31.17% |
| 2019-12-31 | NT$655.64 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Holy Stone Healthcare Co., Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 55811500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$1.46 Billion | 799.70% |
| Total Equity | NT$182.84 Million | 100.00% |
Holy Stone Healthcare Co., Ltd. Competitors by Market Cap
The table below lists competitors of Holy Stone Healthcare Co., Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Audax Renovables S.A.
MC:ADX
|
$11.62 Million |
|
Natural Alternatives International
NASDAQ:NAII
|
$11.62 Million |
|
Samart Telcoms Public Company Limited
BK:SAMTEL
|
$11.63 Million |
|
Hung Thinh Incons JSC
VN:HTN
|
$11.63 Million |
|
IT Link SA
LSE:0NC8
|
$11.62 Million |
|
IMPERO A/S DK -10
F:905
|
$11.61 Million |
|
Pure Hydrogen Corporation Limited
PINK:PHCLF
|
$11.61 Million |
|
Inversora Juramento SA
BA:INVJ
|
$11.61 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Holy Stone Healthcare Co., Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 294,072,000 to 182,842,000, a change of -111,230,000 (-37.8%).
- Net loss of 111,345,000 reduced equity.
- Other comprehensive income increased equity by 3,111,000.
- Other factors decreased equity by 2,996,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-111.34 Million | -60.9% |
| Other Comprehensive Income | NT$3.11 Million | +1.7% |
| Other Changes | NT$-3.00 Million | -1.64% |
| Total Change | NT$- | -37.82% |
Book Value vs Market Value Analysis
This analysis compares Holy Stone Healthcare Co., Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.69x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 1.04x to 5.69x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$6.84 | NT$7.13 | x |
| 2020-12-31 | NT$4.10 | NT$7.13 | x |
| 2021-12-31 | NT$2.40 | NT$7.13 | x |
| 2022-12-31 | NT$4.35 | NT$7.13 | x |
| 2023-12-31 | NT$0.61 | NT$7.13 | x |
| 2024-12-31 | NT$2.07 | NT$7.13 | x |
| 2025-12-31 | NT$1.25 | NT$7.13 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Holy Stone Healthcare Co., Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -60.90%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.21x
- Recent ROE (-60.90%) is above the historical average (-89.99%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -33.09% | -93.36% | 0.31x | 1.14x | NT$-248.21 Million |
| 2020 | -28.53% | -58.10% | 0.42x | 1.16x | NT$-173.88 Million |
| 2021 | -68.66% | -83.52% | 0.63x | 1.30x | NT$-207.72 Million |
| 2022 | -29.26% | -56.59% | 0.44x | 1.18x | NT$-205.22 Million |
| 2023 | -347.10% | -122.15% | 1.18x | 2.41x | NT$-297.71 Million |
| 2024 | -62.40% | -154.50% | 0.34x | 1.20x | NT$-212.90 Million |
| 2025 | -60.90% | 0.00% | 0.00x | 1.21x | NT$-129.63 Million |
Industry Comparison
This section compares Holy Stone Healthcare Co., Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Holy Stone Healthcare Co., Ltd. (4194) | NT$182.84 Million | -33.09% | 0.21x | $11.62 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |